Balyasny Asset Management
TMCI icon

Balyasny Asset Management’s Treace Medical Concepts TMCI Stock Holding History

Balyasny Asset Management’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-66,748
Closed -$560K – 3349
2025
Q1 		$560K Buy
66,748
+55,025
+469% +$495K ﹤0.01% 2235
2024
Q4 		$87.2K Sell
11,723
-189,380
-94% -$1.27M ﹤0.01% 2614
2024
Q3 		$1.17M Buy
+201,103
New +$1.29M ﹤0.01% 1900
2024
Q2 		– Sell
-28,319
Closed -$370K – 3109
2024
Q1 		$370K Buy
28,319
+17,452
+161% +$233K ﹤0.01% 2179
2023
Q4 		$139K Buy
+10,867
New +$110K ﹤0.01% 2358
2022
Q2 		– Sell
-20,109
Closed -$380K – 3181
2022
Q1 		$380K Buy
+20,109
New +$391K ﹤0.01% 1871

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's TMCI Position: Q2 2025 in Review

Balyasny Asset Management sold out of Treace Medical Concepts (TMCI) in Q2 2025, closing a stake of 66,748 shares — an estimated $560K sold.

Balyasny Asset Management first reported a position in TMCI in Q1 2022 and held it in 6 quarters. The position peaked at $1.17M in Q3 2024. 125 funds tracked by Wall St. Rank hold TMCI as of Q2 2025.

  • Balyasny Asset Management reported no remaining Treace Medical Concepts position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 66,748 Treace Medical Concepts shares in Q2 2025, an estimated $560K.
  • Balyasny Asset Management first reported a position in Treace Medical Concepts in Q1 2022 and held it in 6 quarters.
  • Balyasny Asset Management's Treace Medical Concepts position peaked at $1.17M in Q3 2024.
  • 125 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.